About Neurophyxia
Neurophyxia B.V. is an innovative drug development company which focuses on disorders affecting the newborn child. The lead product, 2-iminobiotin (2-IB), addresses the devastating effects of oxygen shortage at birth (perinatal asphyxia).
The company collaborates with established contract research organization in the areas of:
- Manufacturing of drug substance
- Formulation and manufacturing of drug product
- Preclinical safety
- Preclinical efficacy
- Clinical safety (Phase I study)
- Pharmacokinetics